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I. INTRODUCTION
“It made my heart thump, for I was certain it was gold.”1 James Marshall
uttered these words when he discovered gold flakes at the Sutter’s Mill in
Coloma, California.2 As word spread, thousands of miners rushed to California
in search of riches, in what was known as the Gold Rush of 1849.3 Now,
America has a new rush—the “green” rush,4 and once again, it is centered in
the American West.
Marijuana, formally known as cannabis,5 is on the brink of becoming a
legitimate business. Despite a long history of medical use and recreational
consumption dating back to ancient times, marijuana regulation is a recent
development.6 Popularly known as “weed,” many believe cannabis culture is a
counterculture aimed at destroying societal wellbeing in many ways.7
Recent state legalization allowing the recreational use and commercialization
of cannabis in four jurisdictions8 has caught the eye of eager entrepreneurs,
especially innovators of the product. However, legal impediments at the federal
level9 hinder innovation in the cannabis industry from properly budding. As a
result, scarce legal precedent exists for cannabis in the patent law arena. Given
the federal prohibition on marijuana, patenting strains of the cannabis plant,
and its derivative products, would seem to likely be prohibited. The word
“likely” is used because, despite criminal legal impediments, marijuana has been
patented,10 and more cannabis products are patent-pending.11
1 The Discovery of Gold, http://memory.loc.gov/ammem/cbhtml/cbgold.html (last visited Jan.
4, 2015).
2 Id.
3 Id.
4 Medical Marijuana: Will Colorado’s “Green Rush” Last?, http://www.cbsnews.com/videos/medi
cal-marijuana-will-colorados-green-rush-last-3/ (last visited Nov. 15, 2015).
5 Cannabis is used throughout this Note because it is the scientific name for marijuana. The
terms “cannabis” and “marijuana” will be used interchangeably.
6 Dope Etc., FRONTLINE ON PBS, http://www.pbs.org/wgbh/pages/frontline/shows/dope/
etc/cron.html (last visited Oct. 20, 2015). The Pure Food and Drug Act was the first law in
United States history that required cannabis to be labeled in food and drug products. The Pure
Food and Drug Act, 34 Stat. 768 (1906).
7 Marijuana: Public Enemy Number One?, Urban Greenhouse (July 6, 2015), http://urbangreenh
ouse.com/marijuana-public-enemy-number-one/.
8 See COLO. CONST. art. XVIII, § 16 (2013); WASH. ADMIN. CODE §§ 314-55-005 to 314-55540 (2013). Recently, Oregon, Alaska, and the District of Columbia have legalized recreational
marijuana.
9 The Controlled Substances Act, 21 U.S.C. § 801 (1970).
10 Cannabinoids as Antioxidants and Neuroprotectants, U.S. Patent No. 6630507 (filed Feb. 2,
2001) (issued Oct. 7, 2003).
11 See infra Part II.
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While a cannabis method-of-use patent has been granted to the federal
government,12 a unique cannabis strain has never been patented. This Note
seeks to find concrete answers for a grower interested in patenting his or her
unique cannabis strain. Because this is a novel patentable subject matter, this
Note will explore patents in other industries that faced the same legal challenges
afflicting cannabis variety patents. This Note asserts that equal challenges in
other industries burden innovation in the cannabis industry.
This Note concentrates on the legal gray area around cannabis variety
patents and how this uncertainty affects innovation. Part II outlines the legal
environment surrounding marijuana patents and begins with a brief history of
cannabis. Part II will explore the cannabis plant and discuss the federal ban on
marijuana, state legalization for both medicinal and recreational use, and federal
enforcement discretion on cannabis. Part II will survey utility and plant patents
and potentially applicable case law analogous to the novel patentable subject
matter discussed here. Lastly, Part II will conclude by discussing current
patents granted for cannabis and patent-pending developments.
Part III will seek to demystify the legal fog surrounding cannabis variety
patents by identifying the underlying issues and presenting clear answers. Part
III will then conceptualize an analytical framework for cannabis cultivators
navigating this new patentable subject matter. Next, Part III will assert that,
despite federal opposition, cannabis variety patents are legal, given case law
from the Supreme Court and Federal Circuit, as well as the policy
considerations underlying patent law. Finally, Part III will identify legislative
developments that would change the legal environment. Part IV will conclude
that although cannabis cultivation is federally prohibited, policy considerations
underlying plant patents and the case law from the Federal Circuit indicate
cannabis varieties are likely patentable.
II. BACKGROUND
To outline the legal environment surrounding patent law, this Part will look
to the history of cannabis, popular culture, and law that has shaped the current
state of the cannabis industry. Then, this Part will explain the cannabis plant
itself, its physical characteristics, and the patentable end products from the
growth process. This Part will go on to discuss the federal ban on marijuana,
recent state legislation, and the federal governments prosecutorial discretion.
Next, this Part will survey the statutory and policy background of utility and
12 Cannabinoids as Antioxidants and Neuroprotectants, U.S. Patent No. 663507 (filed Feb. 2,
2001) (issued Oct. 7, 2003).
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plant patents, and potentially applicable case law from the Supreme Court and
the Federal Circuit. Lastly, this Part will examine previous patents for cannabis
and patent-pending developments.
A. A BRIEF HISTORY OF CANNABIS LAW AND CULTURE

Cannabis has a history dating back to ancient times. The cannabis plant
likely originated from Southeast Asia.13 The father of Chinese medicine, Shen
Nung, utilized cannabis for medicinal purposes.14 From Asia, the cannabis
plant spread to other parts of the world, including Europe.15 Hemp is a fibrous
by-product of cannabis that has many applications.16 Hemp fibers were used to
make sails for ships, fabric, and other products in colonial America.17 In fact,
George Washington and Thomas Jefferson grew hemp on their plantations.18
Cannabis and most drugs enjoyed no regulation until the twentieth
century.19 After the Shanghai Opium Commission and Hague International
Opium Convention, Congress passed the Harrison Narcotics Tax Act of
1914.20 The Act did not explicitly prohibit marijuana, but placed a tax on
opiates to induce a suppression of drug markets.21
In subsequent years, popular culture shaped legislative efforts concerning
marijuana. In 1936, the film Reefer Madness sought to persuade the American
public of the dangers of marijuana use.22 The film portrayed teenagers who
became addicted to marijuana and committed acts of violence.23 One year later,
Congress passed the Marihuana Tax Act of 1937.24 The Act did not criminalize
13 The Origins of Cannabis, http://www.deamuseum.org/ccp/cannabis/history.html (last visited
Nov. 15, 2015).
14 Yearbook of the United States Department of Agriculture 1913, Internet Archive, 288, https://
archive.org/stream/yoa1913#page/n327/mode/2up (last visited Nov. 15, 2015).
15 Map of Cannabis Spread, http://www.nhm.ac.uk/resources/nature-online/life/plants-fungi/
seeds-of-trade/images/maps/hemp.gif (last visited Nov. 15, 2015).
16 Oscar H. Will, The Forgotten History of Hemp Cultivation in America, http://www.farmcollector.
com/farm-life/strategic-fibers.aspx#axzz3FzIQGeeM (last visited Nov. 15, 2015).
17 Id.
18 Gene Johnson, A History of Pot, from George Washington to Legalizing Ganja, NBC NEWS (Dec. 6,
2012, 6:03 AM), http://usnews.nbcnews.com/_news/2012/12/06/15726635-a-history-of-pot-fr
om-george-washington-to-legalizing-ganja.
19 German Lopez, Timeline: 100 Years of Drug Prohibition, VOX (Sept. 9, 2014, 6:00 AM), http://
www.vox.com/2014/9/9/6104179/the-history-of-the-war-on-drugs.
20 Id.
21 Harrison Narcotics Act of 1914, 38 Stat. 785 (repealed 1970).
22 Reefer Madness, http://www.imdb.com/title/tt0028346/ (last visited Nov. 15, 2015).
23 Id.
24 Marihuana Tax Act of 1937, 50 Stat. 551 (1937), repealed by Leary v. United States, 395 U.S. 6
(1969).
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marijuana, but required people who dealt cannabis and its by-products to
register with the federal government and pay a prohibitive occupational tax.25
In 1969, the Supreme Court, under Chief Justice Earl Warren, struck down the
Marihuana Tax Act. The Court found that the Act violated constitutional
protections of self-incrimination by requiring persons dealing with marijuana to
admit to trafficking by reporting to the Internal Revenue Service.26 This
concern, enunciated by the Warren Court, resonates for cultivators applying for
cannabis variety patents today.27
Marijuana, along with other drugs like LSD, was integral to the
counterculture movement in the 1960’s.28 Along with the Vietnam War,
cannabis usage was at the forefront of the American political conscious.29 Most
notably, Ken Kesey and the Pranksters set out across the country in a “magic”
bus openly promoting the use of psychedelic drugs.30
Cannabis was officially prohibited in the Controlled Substances Act (CSA)
in 1970 during the presidency of Richard Nixon.31 The CSA was the first
congressional act that actually criminalized marijuana.32 The congressional
findings under the CSA state, “[t]he illegal importation, manufacture,
distribution, and possession and improper use of controlled substances have a
substantial and detrimental effect on the health and general welfare of the
American people.”33 Further, Congress enacted the CSA out of concern for the
production and distribution of controlled substances into interstate channels.34
Under the Act, drugs are classified into schedules.35 Schedule I drugs are
substances that have a high potential for abuse, no currently accepted medical
treatment in the United States, and which are not safe for use under medical
supervision.36 Cannabis is classified as a Schedule I drug.37

Id.
Leary v. United States, 395 U.S. 6 (1969).
27 See infra Part III.
28 The 1960’s Hippie Counter Movement, Mortal Journey, http://www.mortaljourney.com/2011/
03/1960-trends/hippie-counter-culture-movement (last visited Oct. 20, 2015).
29 A Brief History of How War Gets Us Hooked on Drugs, Motherboard (Jan. 8, 2013, 4:00 PM),
http://motherboard.vice.com/blog/how-war-getsyou-hooked.
30 MAGIC TRIP (Magnolia Pictures 2011).
31 Controlled Substances Act, 21 U.S.C.S. § 801 (1970).
32 See Lopez, supra note 19.
33 21 U.S.C. § 801(2) (2012).
34 Id.
35 Id. § 812(a).
36 Id. § 812(b)(1).
37 Drug Enforcement Agency, Drug Scheduling, http://www.justice.gov/dea/druginfo/ds.shtml
(last visited Nov. 15, 2015).
25
26
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After the passage of the CSA, President Nixon encouraged Congress to
enact legislation to enforce the CSA.38 He declared that drugs were “public
enemy number one.”39 This federal prohibition on cannabis and other
substances would popularly be known as the “War on Drugs.”40 Later,
Presidents Ronald Reagan and George H.W. Bush increased penalties for drug
laws.41
Recently, however, public support for cannabis has changed. For example, a
1969 Gallup poll found public support for marijuana among twelve percent of
the American populous.42 But, in 2013, the same Gallup poll found fifty-eight
percent of Americans support legalization of marijuana.43 Additionally, sixtynine percent of millennials, people born between 1980 and the year 2000,44
support marijuana legalization.45
While smoked marijuana is classified as a Schedule I narcotic,46 it has never
been directly linked to any deaths.47 In order to be fatal, a marijuana user needs
to consume an estimated 1,000 times the amount required to achieve the
therapeutic/psychotropic effect on a single occasion.48 Many scientific
authorities find substances like alcohol, tobacco, and prescription painkillers
directly lead to more fatalities when they are abused.49 However, cannabis has
increased in potency over the past few decades.50 Today’s cannabis user can
achieve the same psychotropic effect with a smaller dosage than users in
previous decades.51 Thus, cannabis users can consume less marijuana, and

Thirty Years of America’s Drug War (PBS television broadcast 2000).
Id.
40 Id.
41 The Anti-Drug Abuse Act of 1986, 100 Stat. 3207 (1986); George Bush, President of the
United States, Address to the Nation on the National Drug Control Strategy (Sept. 5, 1989).
42 For First Time, Americans Favor Legalizing Marijuana, http://www.gallup.com/poll/165539/fir
st-time-americans-favor-legalizing-marijuana.aspx (last visited Nov. 15, 2015).
43 Id.
44 Millennial Definition, http://www.merriam-webster.com/dictionary/millennial (last visited
Nov. 15, 2015).
45 Views of Same-Sex Marriage, Marijuana Legalization among Generations by Race (Mar. 5, 2014),
http://www.pewsocialtrends.org/2014/03/07/millennials-in-adulthood/sdt-next-america-03-072014-2-11/.
46 Controlled Substances Act, 21 U.S.C.S. § 801 (1970).
47 See Robert S. Gable, The Toxicity of Recreational Drugs, 94 AM. SCI., no. 3, 2006, at 206.
48 Id.
49 Id.
50 Marijuana: Know the Facts, http://www.whitehouse.gov/ondcp/ondcp-fact-sheets/marijuanaknow-the-facts (last visited Nov. 15, 2015).
51 Id.
38
39
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ostensibly achieve the same psychotropic effect without any worry of a fatal
overdose.
However, cannabis consumption likely has harmful health consequences for
the user. Many drug policy authorities find that cannabis is most highly
consumed by a small subset of users,52 who consume marijuana almost on a
daily basis.53 Health authorities believe that a high rate of cannabis
consumption leads to overstimulation of the endo cannabinoid system, resulting
in addiction.54 Frequent users often experience withdrawal.55 Also, cannabis
usage has been shown to have detrimental effects on the developing teenage
brain.56 While cannabis usage among American ages twelve through seventeen
has not increased over the past decade,57 marijuana usage in these
developmental years has been linked to cognitive disorders, like paranoid
schizophrenia.58
Despite studies showing detrimental health impacts on chronic users and
minors, cannabis could be a lucrative industry. The cannabis plant “is
America’s most valuable [cash crop], worth an estimated $35 billion, more than
hay, soybeans, and corn.”59 Marijuana is estimated to potentially generate
billions in both commercial and tax revenue.60 Investment in cannabis has
increased from $500 million to a $7 billion industry in the past two years.61
Additionally, by decriminalizing marijuana, both state and federal governments
52 Market Size and Demand for Marijuana in Colorado, The Marijuana Policy Group, 18 (2014),
https://www.colorado.gov/pacific/sites/default/files/Market%20Size%20and%20Demand%20
Study,%20July%209,%202014%5B1%5D.pdf.
53 Id.
54 Is Marijuana Addictive?, National Institute on Drug Abuse, https://www.drugabuse.gov/publ
ications/research-reports/marijuana/marijuana-addictive (last visited Oct. 20, 2015).
55 Id.
56 Krista M. Lisdahl et al., Dare to delay? The impacts of adolescent alcohol and marijuana use onset on
cognition, brain structure, and function, http://journal.frontiersin.org/Journal/10.3389/fpsyt.2013.000
53/full (last visited Nov. 15, 2015).
57 National survey shows lower rate of illicit drug use among adolescents ages 12 to 17, http://www.samhsa.
gov/newsroom/press-announcements/201409160400 (last visited Nov. 15, 2015).
58 David Bienenstock, The Clinic: A Surprising Link between Marijuana and Schizophrenia, http://
www.hightimes.com/read/clinic-surprising-link-between-marijuana-and-schizophrenia (last visited
Nov. 15, 2015).
59 Adrian A. Ohmer, Investing in Cannabis: Inconsistent Government Regulation and Constraints on
Capital, 3 MICH. J. PRIVATE EQUITY & VENTURE CAPITAL L. 97 (2013) (quoting GREG CAMPBELL,
POT, INC.: INSIDE MEDICAL MARIJUANA, AMERICA’S MOST OUTLAW INDUSTRY, at xxiii (2012))
(internal quotations omitted).
60 Jeffery A. Miron, Milton Friedman, 500+ Economists Call for a Marijuana Debate, http://www.
prohibitioncosts.org (last visited Sept. 28, 2014).
61 Meet the Financier behind a Hot Pot Stock, http://www.bloomberg.com/news/2014-06-18/lega
l-pot-sets-off-penny-stock-frenzy.html (last visited Nov. 15, 2015).
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stand to save billions from law enforcement costs.62 Cannabis is the most
common drug seized at the U.S. border, totaling almost 2 million pounds a
year.63 Further, the federal “drug interdiction budget request for F[iscal] Y[ear]
2011 was . . . $15.55 billion, a 3.5 percent increase from F[iscal] Y[ear] 2010.”64
Legalizing cannabis entirely would eliminate border seizure and enforcement
costs for marijuana from the federal budget.
B. THE CANNABIS PLANT, PSYCHOTROPIC EFFECTS, AND THE GROWTH
PROCESS

Cannabis has three species: cannabis sativa, cannabis indica, and cannabis
ruderalis.65 These species contain compounds called cannabinoids, including
tetrahydrocannibinol (THC), which is the primary psychoactive ingredient that
alters cognitive functioning.66 Depending upon the manner of consumption,
THC and other cannabinoids from the cannabis plant may cause a variety of
effects on the user, including euphoria, increased giggling, lethargy, and
paranoia, among others.67
Reproduction of the cannabis plant occurs either asexually or sexually.68
Asexual reproduction occurs through plant cloning.69 For example, a grower
can take a cutting from the cannabis plant and root it in a contained body of
water known as hydroponics.70 Asexually reproduced cannabis offspring are
genetically identical to the parent plant.71 Conversely, sexual reproduction is the
fusion of gametes between a male and a female plant that results in a seed.72
The offspring will have different physical and genetic characteristics due to the

62 Jeffery A. Miron, The Budgetary Implications of Drug Prohibition, Department of Economics,
Harvard University (2010), http://scholar.harvard.edu/files/miron/files/budget_2010_final_0.
pdf.
63 Marijuana Seizures along the U.S. Mexico Border, http://static.apps.cironline.org/borderseizures/ (last visited Nov. 15, 2015).
64 Ohmer, supra note 59, at 97–98 (citations omitted).
65 GEOFFREY GUY ET AL., THE MEDICINAL USES OF CANNABIS AND CANNABINOIDS 74
(Pharmaceutical Press, 2004).
66 Amresh Shrivastava et al., Cannabis Use and Cognitive Dysfunction, INDIAN J. PSYCHIATRY,
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3221171 (last visited Nov. 15, 2015).
67 Id.
68 R.C. Clarke, Cannabis Botany, WEED FARMER, http://www.weedfarmer.com/cannabis/bot
any_guide.php (last visited Oct. 18, 2015).
69 BUY DUTCH SEEDS, http://www.buydutchseeds.com/growing-guide/cloning-cannabis (last
visited Nov. 15, 2015).
70 Id.
71 Id.
72 Clarke, supra note 68.
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recombination of chromosomes.73 Sexual reproduction between a male and
female cannabis plant leads to new cannabis varieties.74
The marijuana product differs in its physical structure, aroma, and
psychotropic effect and potency based on the growing conditions and
harvesting method.75 Cannabis is grown either in soil with natural nutrients, or
through hydroponics, a method that uses inorganic content like rock wool or
clay pellets.76 During the maturation process, growers can manipulate the onset
of the flowering period by limiting the amount of sunlight and darkness the
plant receives.77 Once the flowering period starts, the unfertilized female part
of the cannabis plant, known as the pistil, is harvested, dried, and cured.78 The
timing of the harvest can change the psychotropic effect.79 The finished
product is a floral cluster, commonly known as the “bud.”80 The “bud” is the
ingestible end-product of the cannabis growing cycle. It can be packaged by
retailers and enjoyed by consumers.
C. THE FEDERAL BAN ON CANNABIS

Under the Controlled Substances Act of 1970, possession, production,
cultivation, and distribution of marijuana is prohibited.81 The executive branch of
the United States charges the Drug Enforcement Administration (DEA) with the
enforcement of the CSA. The DEA classifies drugs according to the “drug’s
acceptable medical use and the drug’s abuse or dependency potential.”82 Again,
cannabis is classified as a Schedule I drug, among other drugs including “heroin,
lysergic acid diethylamide (LSD), . . . methylenedioxymethamphetamine (ecstasy),

Id.
Id.
75 Id.
76 THE DAILY SMOKER, http://www.dailysmoker.com/cannabis-grow-guide/conditions/med
ium (last visited Nov. 15, 2015).
77 Cannabis Life Cycle, MONTANA LEGISLATURE: CHILDREN, FAMILIES, HEALTH, AND HUMAN
SERVICES INTERIM COMMITTEE (June 2009–2010), http://leg.mt.gov/content/Committees/Inter
im/2009_2010/Children_Family/Emerging-Issue/mmga-presentation-cannabis-life-cycle.pdf.
78 Clarke, supra note 68.
79 Id. Depending on the point of harvest, the psychoactive effect can be a “light cerebral
high,” or an “intense body effect.” This means a cannabis grower can vary the effect of their
product to suit different consumers.
80 Id.
81 21 U.S.C. § 841.
82 Drug Scheduling, DRUG ENFORCEMENT AGENCY, http://www.justice.gov/dea/druginfo/ds.
shtml (last visited Nov. 15, 2015).
73
74
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methaqualone, and peyote.”83
The federal government imposes severe
punishments on those who possess, produce, or distribute cannabis.84
Under the CSA, an interested party can change a drug’s schedule through an
administrative mechanism.85 Under this mechanism, an interested party can
initiate a process to add, delete, or change the schedule of a controlled
substance.86 National Organization for the Reform of Marijuana Laws,
otherwise known as NORML, and other organizations invoked this
administrative mechanism in 1972 to change the classification of cannabis.87
After sixteen years of court proceedings and negotiations, Administrative Law
Judge Francis L. Young issued a decision.88 His opinion discussed three issues:
one principal issue and two subsidiary issues.89 The principal issue concerned
“whether the marijuana plant, considered as a whole, may lawfully be
transferred from Schedule I to Schedule II.”90 The two subsidiary issues
regarded “whether [cannabis] . . . has an accepted medical use in treatment in
the United States”91 and “whether there is a lack of accepted safety use of the
marijuana plant under medical supervision.”92
After thirty-eight findings of fact,93 Judge Young found, by a preponderance
of the evidence, that cannabis has “an accepted medical use in treatment in the
United States in effecting relief for cancer patients.”94 In assessing the safety of
cannabis use, Judge Young found “no record in . . . extensive medical literature
describing a proven, documented cannabis-induced fatality.”95 While the DEA
argued it needed more studies and tests to determine if cannabis can be
consumed safely, Judge Young found “it is unrealistic and unreasonable to
require unanimity of [medical professional] opinion[s]”96 on the issue of safety.

Id.
See 21 U.S.C. § 841 (2012). The penalty for trafficking of 50 kilograms of marijuana or 10
kilograms of hashish is not more than five years imprisonment and a fine up to $250,000.
85 Id. § 814.
86 Ohmer, supra note 59, at 100–01 (citing 21 U.S.C. § 814).
87 Id. at 101.
88 Id.
89 Marijuana Rescheduling Petition, Dep’t of Justice, Drug Enforcement Admin., No. 86-22, at
7 (Sept. 6, 1988).
90 Id.
91 Id.
92 Id.
93 Id. at 10–26.
94 Id. at 34.
95 Id. at 56.
96 Id. at 66.
83
84
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Judge Young concluded “the provisions of the [CSA] permit and require the
transfer of marijuana from Schedule I to Schedule II.”97
Despite Judge Young’s ruling, the DEA denied a petition to change
cannabis to a Schedule II drug following the administrative opinion.98 The
DEA issued the following statement:
The Administrator rejects the administrative law judge’s findings
and conclusions. They were erroneous; they were not based
upon credible evidence; nor were they based upon evidence in
the record as a whole. Therefore, in this case, they carry no
weight and do not represent the position of the agency or its
Administrator.99
The D.C. Circuit Court of Appeals affirmed the decision of the DEA and
subsequently denied the petitioners’ petition for review.100 As a result of this
denial, cannabis remains a Schedule I controlled substance.
D. STATE LEGALIZATION OF CANNABIS FOR MEDICAL AND RECREATIONAL
USE

Justice Brandeis once said,
It is one of the happy incidents of the federal system that a single
courageous state may, if its citizens choose, serve as a laboratory;
and try novel social and economic experiments without risk to
the rest of the country. This Court has the power to prevent an
experiment.101
This famous statement likely provided the foundation for novel state legislation
in the area of cannabis. The first experiment came in California in 1996, which
legalized cannabis for medical purposes.102 A bevy of states then followed

Id. at 67.
Marijuana Scheduling Petition; Denial of Petition, 54 Fed. Reg. 53,767, 53,783 (Dep’t of
Justice, Drug Enforcement Admin., Dec. 29, 1989).
99 Id.
100 Ohmer, supra note 59, at 102.
101 New State Ice Co. v. Liebmann, 285 U.S. 262, 311 (1932) (Brandeis, J., dissenting)
(explaining that states have agency to enact laws in novel areas of law).
102 Ohmer, supra note 59, at 102.
97
98
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California’s lead.103 These states have removed criminal consequences for
possession, production, and use as long as a doctor has recommended use for
medical issues.104
Although state legislation has sanctioned cultivation and possession of
cannabis within its borders, the federal government reserves the power to
regulate interstate cannabis. In 2005, the Supreme Court upheld Congress’s
power to regulate marijuana under the interstate Commerce Clause in Gonzales
v. Raich.105 Here, California passed Proposition 215, which was codified as the
Compassionate Use Act of 1996.106 The Act allowed ill patients to have access
to marijuana for medicinal purposes.107 Also, the Act created an exemption to
criminal prosecution for doctors and allowed patients and caregivers to grow
marijuana with a prescription.108
The Court of Appeals for the Ninth Circuit reversed the district court and
held that homegrown medical marijuana was a “separate and distinct class of
activities”109 beyond the reach of federal power.110 In an application of the
aggregation theory under Wickard v. Filburn,111 the United States Supreme Court
found the application of the Controlled Substances Act to intrastate growers is
within the reach of Federal regulation because Congress has the power to
regulate even intrastate cannabis activities that substantially affect interstate
commerce.112 In analogizing marijuana in this case to wheat production in
Wickard, the Court found the purpose of the CSA was to regulate the supply of
controlled substances into the drug market.113 Subsequently, the Court found

103 Id. at 102–03. Other states that legalized cannabis for medical use include Oregon (1998);
Alaska (1998); Washington (1998); Maine (1999); Hawaii (2000); Colorado (2000); Nevada (2000);
Vermont (2004); Montana (2004); Rhode Island (2006); New Mexico (2007); Michigan (2008);
Arizona (2010); New Jersey (2010); Delaware (2011); Connecticut (2012); Massachusetts (2012);
Illinois (2013); New Hampshire (2013); Maryland (2014); Minnesota (2014); and New York
(2014). States with limited access to Medical Marijuana include Alabama, Florida, Georgia, Iowa,
Kentucky, Louisiana, Mississippi, Missouri, Oklahoma, South Carolina, Tennessee, Texas, Utah,
Virginia, Wisconsin, and Wyoming. State Medical Marijuana Laws, National Conference of State
Legislatures, http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx (last visited
Oct. 20, 2015).
104 Ohmer, supra note 59, at 103.
105 545 U.S. 1 (2005).
106 Id. at 5.
107 Id.
108 Id.
109 Raich v. Ashcroft, 352 F.3d 1222, 1228 (2003).
110 Id. at 1228.
111 See 317 U.S. 111 (1942).
112 Gonzales, 545 U.S. at 17.
113 Id. at 19.

Published by Digital Commons @ University of Georgia School of Law, 2015

13

Journal of Intellectual Property Law, Vol. 23, Iss. 1 [2015], Art. 7

182

J. INTELL. PROP. L.

[Vol. 23:169

there was a rational basis for Congress to believe that leaving homegrown
marijuana outside the CSA would have an effect on drug markets when viewed
in the aggregate.114 Further, the Court stated the CSA is a constitutionally valid
statutory scheme and that Congress had the power to make all laws necessary
and proper to enforce the CSA when it enacted the CSA.115
Even though the majority conceded that marijuana has a beneficial
medicinal purpose, it found the federal government can criminalize marijuana
under the CSA for any purpose.116 In his opinion, Justice Stevens suggested
that if federal regulation on medical marijuana is “beyond the ‘outer limits’ of
Congress’ Commerce Clause authority,”117 then “marijuana . . . for recreational
purposes is also beyond those ‘outer limits,’ whether or not a State elects to
authorize or even regulate such use.”118
Furthermore, in upholding the application of the CSA to intrastate activities,
Justice Stevens invoked the Supremacy Clause by reiterating, “that if there is
any conflict between federal and state law, federal law shall prevail.”119 Even
though respondents in this case were comporting with the California regulatory
scheme, respondents were not beyond federal jurisdiction under the CSA.120
In dicta, Justice Stevens commented that medical discretion to prescribe
marijuana was “open-ended.”121 Thus, doctors could prescribe cannabis for
recreational uses and increase the supply of marijuana into drug markets.122
Despite the Gonzales decision, California maintained its state law permitting
medical marijuana. However, this decision created a legal quandary for
dispensaries in California and other states sanctioning medical marijuana. While
homegrown marijuana was permitted for sick patients under state law, cannabis
cultivators could still be arrested and prosecuted by the federal government
under the CSA.123

Id.
Id. at 22. Congress has the power “[t]o make all Laws which shall be necessary and proper
for carrying into Execution the foregoing Powers, and all other Powers vested by this
Constitution in the Government of the United States, or in any Department or Officer thereof.”
U.S. CONST. art. I, § 8, cl. 18.
116 Gonzales, 545 U.S. at 27.
117 Id. at 28.
118 Id.
119 Id. at 29.
120 Id.
121 Id. at 30–31.
122 Id. at 31.
123 Id.
114
115
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Nevertheless, Colorado and Washington legalized marijuana for recreational
use in 2013.124 In Colorado, the state legalized marijuana through amendments
to its constitution, “[i]n the interest of the efficient use of law enforcement
resources, enhancing revenue for public purposes, and individual freedom.”125
As long as a person is over the age of twenty-one, he or she will be legally
allowed to consume marijuana, subject to certain restrictions.126 Additionally,
said person can possess six cannabis plants.127
The state constitutional provision regulates marijuana in a manner consistent
with alcohol.128 Production and cultivation for commercial use requires a
license from the state.129 The provision defines a “marijuana establishment” for
recreational use under four different types: “a marijuana cultivation facility, a
marijuana testing facility, marijuana product manufacturing facility, or a retail
marijuana store.”130 These definitions essentially define the supply chain of
marijuana distribution. Under the provision, a cultivation facility is the only
“entity licensed to cultivate, prepare, package, and sell marijuana” to other
facilities, but it cannot sell directly to the consumer. Only a retail store can sell
to the consumer.131 The product manufacturing facility cannot cultivate
marijuana; it can only package and prepare the product for retailers.132 The
separation of entities allows Colorado to regulate the flow of marijuana from
producer to consumer and prohibit wholesale distribution directly to the
consumer.
In Washington, voters approved Initiative Measure No. 502, which
“intend[s] to stop treating adult marijuana use as a crime.”133 Initiative 502 is
similar to the Colorado constitutional provision with immaterial changes in
terminology. The procedures to obtain a marijuana license are explicitly

124 See COLO. CONST. art. XVIII, § 16 (2013); WASH. ADMIN. CODE §§ 314-55-005 through 31455-540 (2013). As of November 5th, 2014, Oregon, Alaska, and the District of Columbia have
legalized recreational marijuana.
125 COLO. CONST. art. XVIII, § 16(1)(a).
126 Id.
These certain restrictions include driving under the influence of marijuana, giving
marijuana to a minor, requiring employers to permit use of marijuana in employment contracts,
and other issues concerning the control of property. Id. § 16(6).
127 Id. § 16(3)(b).
128 Id. § 16(1)(b).
129 Id. § 16(4)(c). This is subject to “article 4 of title 24 of the Colorado Administrative
Procedure Act or any successor provision.” Id. § 16(5)(a)(1).
130 Id. § 16(2)(i).
131 Id. § 16(2)(n).
132 Id. § 16(2)(j).
133 Initiative Measure No. 502, http://sos.wa.gov/_assets/elections/initiatives/i502.pdf (last
visited Nov. 15, 2015).
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codified in Washington’s Administrative Code.134 Like Colorado, Washington
regulates marijuana similarly to alcohol under its Liquor Control Board.135 One
material difference from Colorado is that Initiative 502 intends for tax revenue
to fund “education, health care, research, and substance abuse prevention.”136
In Colorado, tax revenue from cannabis will go to school construction
projects.137
While Colorado and Washington have enacted liberal marijuana legislation
in the face of the Gonzales decision, persons exercising rights afforded by
Colorado and Washington are still subject to federal prohibitions.138 Thus, the
federal government may exercise prosecutorial discretion to enforce the CSA.139
This means that growers may face federal criminal prosecution, even though
recreational cannabis is legal in their state.
E. THE UNITED STATES DEPARTMENT OF JUSTICE’S PROSECUTORIAL
DISCRETION TO ENFORCE THE CONTROLLED SUBSTANCES ACT

Despite state legalization, the federal government can circumvent state law
and enforce the Controlled Substances Act. The power to enforce the CSA
comes from the President of the United States, who has the power to execute
federal laws.140 The Department of Justice is the extension of this presidential
power, headed by the Attorney General.141
Under former U.S. Attorney General Eric Holder,142 the Department of
Justice issued press releases giving guidance for marijuana drug enforcement in
states where marijuana has been legalized.143 In a memorandum released on
August 29, 2013, the Department of Justice stated:
Accordingly, in exercising prosecutorial discretion, prosecutors
should not consider the size or commercial nature of a marijuana
operation alone as a proxy for assessing whether marijuana
See WASH. ADMIN. CODE §§ 314-55-005 through 314-55-540 (2013).
See supra note 124 and accompanying text.
136 See supra note 124 and accompanying text.
137 COLO. CONST. art. XVIII, § 16(5)(d).
138 Gonzales, 545 U.S. at 29.
139 Id.
140 U.S. CONST. art. II.
141 28 U.S.C. § 503.
142 Holder announced his resignation on September 25, 2013. Attorney General Eric Holder
Announces Resignation, http://www.cnn.com/2014/09/25/politics/eric-holder-resignation/ (last
visited Nov. 15, 2015). He was succeeded by Loretta E. Lynch.
143 James M. Cole, Guidance Regarding Marijuana Enforcement, Department of Justice (2013),
http://www.justice.gov/iso/opa/resources/3052013829132756857467.pdf.
134
135
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trafficking
implicates
the
Department’s
enforcement
priorities . . . Rather, prosecutors should continue to review
marijuana cases on a case-by-case basis and weigh all available
information and evidence, including, but not limited to, whether
the operation is demonstrably in compliance with a strong and
effective state regulatory system.144
While not totally eliminating its ability to enforce the CSA against state
dispensaries, the Department of Justice has effectively relaxed its role in
prosecuting state cannabis business entities comporting with a state regulatory
scheme.145 Further, Department of Justice officials stated, “While the
prosecution of drug traffickers remains an important priority, the president and
the administration believe that targeting individual marijuana users, especially
those with serious illnesses and their caregivers, is not the best allocation of
federal law enforcement resources.”146
However, in the same memorandum, the Department of Justice made clear
that it retains the right to enforcement in many scenarios.147 While
prosecutorial discretion has relaxed, the Department of Justice remains vague
on which specific cases it will prosecute. In other words, some prosecutors
may still raid dispensaries that comport with state regulatory schemes, despite
the memorandum. The effect of this memo on those applying for cannabis
variety patents is unclear and speculative at best.

Id.
Justice Department Announces Update to Marijuana Enforcement Policy, United States Department
of Justice (2013), http://www.justice.gov/opa/pr/justice-departmentannounces-update-marijuan
a-enforcement-policy (arguing that federal government’s limited prosecutorial resources should
be utilized on enforcement priorities and leave state and local law enforcement agencies to handle
intrastate and local marijuana activity).
146 Nicole Flatow, BREAKING: Justice Department Won’t Challenge State Marijuana Laws, Announces
Major Shift In Law Enforcement Policy, THINK PROGRESS, http://thinkprogress.org/justice/2013/
08/29/2551851/breaking-justice-department-wont-challenge-state-marijuana-laws-announces-ma
jor-shift-law-enforcement-policy/ (last visited Nov. 15, 2015).
147 Cole, supra note 143, at 1–2. The memorandum sets out situations where enforcement is a
priority, including preventing the distribution of marijuana to minors, the sale of marijuana from
going to criminal enterprises, gangs, and cartels, the diversion of marijuana to states where it is
legal under state law in some form to other states, state-authorized marijuana activity from being
used as a cover or pretext for the trafficking of other illegal drugs or other illegal activity, violence
and firearms in the cultivation and distribution of marijuana, drugged driving and exacerbation of
other adverse public health consequences associated with marijuana use, the growing or marijuana
on public lands and the attendant public safety and environmental dangers posed by marijuana
production on public lands, and marijuana possession or use on federal property.
144
145
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In a farewell interview with the press, Eric Holder discussed rescheduling
marijuana by questioning, “whether or not marijuana is as serious a drug as is
heroin.”148 He further stated, “The question of whether or not they should be
in the same category is something that I think we need to ask ourselves, and use
science as the basis for making that determination.”149
While dialogue and discussions indicate changing politics and enforcement
policy, cannabis cultivation is still a prosecutable defense under the CSA.150
True change in this area of law can only be changed by congressional legislation
or rescheduling cannabis from Schedule I.
F. THE LEGAL ENVIRONMENT BEHIND UTILITY AND PLANT PATENTS

The United States Constitution explicitly provides for patents.151 The
pertinent section states, “[t]o promote the [p]rogress of [s]cience and useful
[a]rts, by securing for . . . [i]nventors the exclusive [r]ight to their respective
[w]ritings and [d]iscoveries.”152 The underlying rationale for this constitutional
provision is an economic incentives theory.153 By providing a limited monopoly
to inventors, patents encourage invention and innovation of works of utilitarian
value to the public interest.154 Adam Smith argued for “the need for limited
monopolies to promote innovation and commerce requiring substantial upfront investments and risk.”155 Another famous economist, John Stuart Mill,
found “a temporary ‘exclusive privilege’ was preferable to general governmental
awards on the ground that it avoided ‘discretion’ and ensured that the reward to
the inventor was proportional to the ‘usefulness’ to consumers of the
invention.”156 If patents extend to the cannabis industry, a grower will likely
want to capitalize on his or her strain of cannabis by monopolizing it. This may
give the necessary spark needed to see rapid innovations in cannabis varieties.

148 Interview by Katie Couric with Eric Holder, U.S. Attorney General (Sept. 25, 2014), http://
news.yahoo.com/video/holder-disproportionately-longer-prison-sentences-053241539.html.
149 Id.
150 21 U.S.C. § 841 (2010).
151 U.S. CONST. art. I, § 8, cl. 8.
152 Id.
153 Michael A. Sartori, An Economic Incentives Analysis of the Jury’s Role in Patent Litigation, 79 J. PAT.
& TRADEMARK OFF. SOC’Y 331, 336 (1997) (discussing the economic incentives theory in patent
law).
154 Id. at 339.
155 Peter Menhall, Intellectual Property: General Theories 131 (1991), available at http://levine.sscnet.
ucla.edu/archive/ittheory.pdf.
156 Id. at 132.
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Patent issues, from application to infringement, are exclusively within
federal jurisdiction.157 Applications for patents are reviewed by a federal agency
known as the United States Patent and Trademark Office (USPTO).158 The
Federal Circuit is a special court that receives appeals of patent cases.159
A cannabis cultivator could protect his or her cannabis strain through a
utility patent,160 the Plant Patent Act161 (PPA), or the Plant Variety Protection
Act162 (PVPA). Utility patents are governed by 35 U.S.C. § 101,163 which states,
“[w]hoever invents or discovers any new and useful process, machine,
manufacture, or composition of matter, or any new and useful improvement
thereof, may obtain a patent therefor, subject to the conditions and
requirements of this title.”164 Abstract ideas, physical phenomena, and laws of
nature, including compounds naturally occurring in nature, are not
patentable.165 Utility patents must satisfy four elements: novel, statutory, useful,
and nonobvious.166
To receive a patent, an invention or innovation must be novel.167 Per 35
U.S.C. § 102, an invention cannot be patented if “the claimed invention was
patented, described in a printed publication, or in public use, on sale, or
otherwise available to the public before the effective filing date of the claimed
invention”168 or “the claimed invention was described in a patent . . . or in an
application for patent published . . . in which the patent . . . names another
inventor and was . . . filed before the . . . filing date.”169 Likewise, under
§ 102(b), an invention is ineligible for patent protection where public use of the
invention, prior to applying for a patent, has led people to believe that the
invention is available to all.170 This requirement protects the public’s
expectations while also encouraging prompt disclosure of new and useful
157 Mark J. Henry, State Courts Hearing Patent Cases: A Cry for Help to the Federal Circuit, 101 DICK.
L. REV. 41, 44 (1996).
158 Note, The Disclosure Function of the Patent System (Or Lack Thereof), 118 HARV. L. REV. 2007,
2009 (2005).
159 Id. at 2011–12.
160 35 U.S.C. § 101 (2012).
161 Townsend-Purnell Plant Patent Act, 35 U.S.C. §§ 161–164 (1954).
162 See 7 U.S.C.A. §§ 2321–2582 (2015).
163 35 U.S.C. § 101 (2012).
164 Id.
165 David Tyler, Patent Requirement, BITLAW, http://bitlaw.com/patent/requirements.html (last
visited Nov. 15, 2015).
166 Id.
167 Id.
168 35 U.S.C. § 102(a)(1) (2012).
169 Id. § 102(a)(2).
170 See Tyler, supra note 165.
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information.171 This requirement is similar to the novelty requirement, except it
looks backward from the date of application rather than the date of
invention.172
The “useful” requirement is easily satisfied if the invention under the patent
statute has any utilitarian purpose.173 Many courts have found that the term
“useful” in the patent statute is laden with ambiguity.174 A patent discharges the
obligation of usefulness if it sets forth a specific and substantial utility.175
Specific utility is defined by specificity to the subject matter claimed176 and can
“provide a well-defined and particular benefit to the public.”177 Substantial
utility in “[a patent] application must show that an invention is useful to the
public as disclosed in its current form, not that it may prove useful at some
future date after further research.”178 But, a court is more likely to find an
invention or innovation is not useful if it is an inoperative invention, meaning it
does not operate to produce the results claimed by the patent applicant.179 As
long as the invention or innovation operates as stated in the patent application
and satisfies a specific and substantial utility, the standard for usefulness is
usually met in patent applications.
Finally, under 35 U.S.C. § 103,
[a] patent for a[n] invention may not be obtained . . . if the
differences between the claimed invention and the prior art are
such that the claimed invention . . . would have been obvious
before the effective filing date . . . to a person having ordinary
skill in the art.180
The nonobvious requirement is the most difficult barrier to a utility patent. In a
nonobvious determination, patent examiners will review previous patents to
Id.
Id.
173 Id. This will be explored in greater detail in Part II.G.
174 Brenner v. Manson, 383 U.S. 519, 529 (1966) (simply everyday word like “useful” can be
“pregnant with ambiguity when applied to the facts of life”).
175 2107.01 General Principles Governing Utility Rejections (R-11.2013), United States Patent and
Trademark Office (Mar. 27, 2014, 10:10 AM), http://www.uspto.gov/web/offices/pac/mpep/
s2107.html.
176 Id.
177 In re Fisher, 421 F.3d 1365, 1371 (Fed. Cir. 2005).
178 Id. at 1371.
179 2107.01 General Principles Governing Utility Rejections (R-11.2013), supra note 175.
In re
Harwood, 390 F.2d 985, 989, 156 U.S.P.Q. 673, 676 (C.C.P.A. 1968) (“An inoperative invention,
of course, does not satisfy the requirement of 35 U.S.C. § 101 that an invention be useful.”).
180 35 U.S.C. § 103 (2012).
171
172
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find similarities to the claimed invention.181 If all the features from the claimed
invention can be found in a single patent, then it will be rejected. Otherwise,
the examiner will combine two or more patents and attempt to find all the
claimed invention’s features in the combined patents.182 If the examiner
successfully finds all the features through a combination of patents, the patent
examiner will reject the claimed invention because it is an obvious combination
of features in the prior art.183 If the claimed invention overcomes the patent
examiner’s process, then it will fulfill this element.
Besides a utility patent, a cannabis cultivator could get a plant patent under
the PPA. The PPA became law in 1930.184 It was the first legislation in the
world to afford patent rights to plant breeders and ensure protection for
innovators in agriculture.185 The statute states “whoever invents or discovers
and asexually reproduces any distinct and new variety of plant, including
cultivated sports, mutants, hybrids, and newly found seedlings . . . may obtain a
patent therefor.”186 Many courts interpret the phrase “invents or discovers”187
to mean “uniqueness of the plant and subsequent asexual reproduction of the
plant.”188 In order to comport with the phrase ‘asexual reproduction’ in the
Act, courts deem acceptable methods of reproduction to be “grafting, budding,
cutting, layering, division, and the like.”189 The Act recognizes the plant
breeder’s work “in aid of nature” should be granted patent protection.190 In
subsequent years, Congress further addressed plant patents in general patent
law.191 It changed the protections for plant patents from the “ ‘exclusive right’
to the ‘right to exclude,’ based on court interpretations of the right conferred to
utility patents.”192 Later on, Congress disallowed patent protection for plants in
an uncultivated state.193 As a result, plants in a cultivated, fully-formed state

See Tyler, supra note 165.
Id.
183 Id.
184 Ann K. Wooster, Annotation, Construction and Application of Plant Patent Act (35 U.S.C.A.
§§ 161 et seq.), 135 A.L.R. FED. 273 (1996).
185 Id.
186 35 U.S.C. § 161 (2012).
187 Id.
188 Wooster, supra note 184, § 2, at 282.
189 Id.
190 Id.
191 Id. (citing the Act of July 19, 1952 ch. 950, 66 Stat. 804).
192 Id.
193 Id. Uncultivated plant varieties are “wild varieties discovered by [a] plant explorer or other
person who has in no way engaged either in plant cultivation or care and who has in no other way
facilitated nature in the creation of a new and desirable variety.” S. REP. NO. 71-315, at 3 (1930).
181
182
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and later asexually reproduced were given more expanded protections.194 The
PPA limits asexual reproduction to that of one mother plant.195 In 1995, the
Federal Circuit reaffirmed in Imazio Nursery, Inc. v. Dania Greenhouse that only
asexual reproduction from one mother plant is protected under the PPA.196
In 1970, Congress sought to expand plant protections by passing the
PVPA.197 Unlike the PPA, the PVPA affords “patent-like protections to novel
varieties of sexually reproduced plants.”198 Thus, seeds and other forms of
uncultivated, sexually reproduced plants, specifically removed from the PPA, can
receive patent-like protections.199 The patent-like protections include “exclud[ing]
others from selling the variety, . . . offering it for sale, . . . reproducing
it, . . . importing it, . . . exporting it, or using it [to] produc[e] (as distinguished
from developing) a hybrid or different variety therefrom” for a period of twenty
years.200 The purpose of the PVPA is to provide developers of novel plant
varieties with “adequate encouragement for research, and for marketing when
appropriate, to yield for the public the benefits of new varieties.”201 Subsequent
amendments to the PVPA require that the plant variety be “new, distinct,
uniform, and stable.”202 Thus, the PVPA would protect a sexually reproduced
plant from distinct male and female plants, but not a clone grown from a cutting
of a single mother plant.
However, protection for plants patented under PVPA do not originate from
the USPTO. Rather, this protection comes from the Department of
Agriculture.203 Therefore, PVPA protections are patent-like, but are not true
patents in themselves. Thus, PVP certificates are less protective of legal rights
than utility and plant patents because they are not regulated and enforced with
the USPTO’s expertise.
The Federal Circuit and the United States Supreme Court have not
addressed whether marijuana strains are patentable. However, case law
involving corn serves as guidance in this area by analogy. The Supreme Court
upheld the patentability of sexually reproduced plants in J.E.M. Ag Supply v.
Pioneer Hi-Bred International, Inc. in 2001 (Pioneer). Pioneer Hi-Bred International
Wooster, supra note 184. at 282.
Id. § 9.
196 Id. § 5, at 287 (citing Imazio Nursery, Inc. v. Dania Greenhouse, 69 F.3d 1560 (Fed. Cir.
1995)).
197 Id. at 343.
198 Id. § 2, at 282.
199 Id.
200 See 7 U.S.C.A. § 2483 (1970).
201 See id. § 2581.
202 Wooster, supra note 184.
203 7 U.S.C.A. § 2321 (1970).
194
195
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was a corporation selling seeds from its hybrid corn plant 3394.204 Pioneer sold
the seeds under a license that did not allow “the use of such seed or the
progeny thereof for propagation or seed multiplication or for production or
development of a hybrid or different variety of seed.”205 The petitioner, J.E.M.
Ag Supply (J.E.M.) doing business as Farm Advantage, purchased these seeds
from Pioneer in bags with the license agreement.206 J.E.M. resold the bags, and
was subsequently sued by Pioneer, which claimed patent infringement.207
J.E.M. entered a counterclaim of patent invalidity stating that sexuallyreproduced plants are not patentable subject matter under 35 U.S.C. § 101.208
The Supreme Court affirmed the judgments of the district court and court of
appeals, which granted summary judgment to Pioneer.209
In Pioneer, the Supreme Court cited Diamond v. Chakrabarty,210 which found
that § 101 of the patent statute should be broadly interpreted.211 The
Chakrabarty Court found that Congress does not need to expressly authorize
protection of a particular patentable subject matter.212 Prior to passage of the
PPA in 1930, the Chakrabarty Court explained that two factors precluded plants
from patentability.213 First, plants were believed to be products of nature, and
thus, not patentable subject-matter.214 Second, plants could not fulfill the
description requirement in patent law.215 While Congress did not believe plants
were patentable prior to 1930, the Chakrabarty Court found “the relevant
distinction was not between living and inanimate things, but between products
of nature . . . and human-made inventions.”216 After the Chakrabarty decision,
the USPTO found that plants are patentable subject matter under § 101 because
they fall within the meaning of “manufacture” or “composition of matter” as
used in the statute.217 Thus, a plant patent may achieve the status of a utility
patent.

204 J.E.M. Ag Supply, Inc. v. Pioneer Hi-Bred International, Inc., 534 U.S. 124 (2001). The
patent for this seed is U.S. Patent No. 5,491,295, cols. 2–3, at 29–30.
205 Pioneer, 534 U.S. at 128 (quoting U.S. Patent No. 5,491,295 at 51).
206 Id.
207 Id.
208 Id. at 129.
209 Id. at 129–30.
210 447 U.S. 303 (1980).
211 Pioneer, 534 U.S. at 130.
212 Id.
213 Id. at 134 (quoting Chakrabarty, 447 U.S. at 311–12 (1980)).
214 Id.
215 Id.
216 Chakrabarty, 447 U.S. at 313.
217 Pioneer, 534 U.S. at 131.
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Even though the PPA was codified in a separate chapter, Chapter 15, of
Title 35, the Pioneer Court found this did not change the substantive rights for a
plant patent. The Court held “[p]lant patents under the PPA . . . have very
limited coverage and less stringent requirements than § 101 utility patents.”218
This meant that plant patents were easier to obtain, but less secure then a utility
patent. Additionally, the Court found that Chapter 15 did not state that plant
patents were the exclusive means for protection for plants.219 Thus, plants
could obtain utility patent protection in the alternative.
J.E.M., however, argued the PPA and PVPA provide the exclusive means
for protecting plants and excluded utility patent protection under § 101.220
J.E.M. advanced that plants were not covered in § 101 prior to the passage of
the PPA, but the Court rejected this contention and concluded the utility patent
statute was dynamic enough to encompass new and unanticipated inventions.221
Second, J.E.M. argued the PPA’s limitation on protection for sexually
reproduced plants would be meaningless if Congress wanted the utility patent
statute to encompass sexually reproduced plants. However, the Court
examined the legislative context surrounding the PPA’s enactment and
concluded that Congress had very different concerns in mind: Congress felt that
patenting sexually reproduced seeds was economically infeasible because there
was no established market for such seeds.222 The Court found little evidence to
indicate Congress intentionally precluded patent protection for sexually
reproduced plants when it limited the PPA to asexually reproduced plants.223
Finally, although the Congress codified plant patents in § 161, the Court held
plant patents still fell within the expansive language of § 101.224
In the alternative, J.E.M. argued that Congress intended to deny broader
protections for utility patent protection because Congress specifically enacted
the PVPA, which limited patent-like protection for certain sexually reproduced
plants.225 The Court held that the PVPA does not explicitly provide that it is

Id. at 133.
Id.
220 Id.
221 Id. at 135 (“Whatever Congress may have believed about the state of patent law and the
science of plant breeding in 1930, plants have always had the potential to fall within the general
subject matter of § 101, which is a dynamic provision designed to encompass new and unforeseen
inventions.”).
222 Id. at 136.
223 Id. at 137.
224 Id. at 137–38.
225 Id. at 138.
218
219
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the exclusive means of protecting sexually reproduced plants.226 It also held
utility patents provide a larger scope of protection than a Plant Variety
Protection (PVP) Certificate.227 Utility patents for plants are more difficult to
obtain than a PVP certificate because a utility patent must be “new, useful, and
nonobvious,”228 and breeders must describe the plant in enough detail to enable
future breeders to make and use the invention after the patent expires.229 A
plant breeder need only show the plant variety is “new, distinct, uniform, and
stable”230 for a PVP certificate.231 While protections for the PVPA were
increased,232 the PVP certificate does not grant full protections enjoyed by
utility patents.233 The court referenced an example to explain the difference in
protection between PVP certificates and utility patents. PVP certificates differ
“because a [random] breeder can use a plant that is protected by a PVP
certificate to ‘develop’ a new inbred line while he cannot use a plant patented
under § 101 for such a purpose.”234 Under a utility patent, there are no
exemptions for research or saving seed.235 PVP certificates do have an
exemption for research and saving seeds.236 Further, PVP have no patent
claims.237 Patent claims, under 35 U.S.C. § 112(b), state “[t]he specification shall
conclude with one or more claims particularly pointing out and distinctly
claiming the subject matter which the inventor or a joint inventor regards as the
invention.”238 These patent claims set forth the metes and bounds of
protection.239 In other words, patent claims define the scope of what the patent

226 Id. (“First, nowhere does the PVPA purport to provide the exclusive statutory means of
protecting sexually reproduced plants.”).
227 Id. (“Because it is harder to qualify for a utility patent than for a Plant Variety Protection
(PVP) certificate, it only makes sense that utility patens would confer a greater scope of
protection.”).
228 Id. at 142 (citing 35 U.S.C. §§ 101–103).
229 Id. (citing 35 U.S.C. § 112).
230 See 7 U.S.C. § 2402(a).
231 Pioneer, 534 U.S. at 142.
232 The PVPA also protects “any variety that is essentially derived from a protected variety,” 7
U.S.C. § 2402(c)(1), and “any variety whose production requires the repeated use of a protected
variety,” id. § 2402(c)(3). See Plant Variety Protection Act Amendments of 1994, § 9, 108 Stat.
3142.
233 Pioneer, 534 U.S. at 143.
234 Id.
235 Id.
236 Plant v. Utility Patents, PERENNIAL PATENTS, http://perennialpatents.com/plantpatent-v-utili
ty-patents/ (last visited Oct. 20, 2015).
237 Id.
238 35 U.S.C. § 112(b) (2012).
239 Plant v. Utility Patents, supra note 236.
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does and does not cover.240 Plant patents have one claim.241 Utility patents are
much broader in their protection because they can have multiple claims.242
Additionally, utility patents can cover different types of claims, including seed
deposit claims, trait claims, breeding methods, food product claims.243 Further,
the Court also noted the USPTO has assigned utility plant patents for a
significant time frame244 without inconsistent legislation from Congress,
indicating congressional acquiescence to the PPA and PVPA.245 Thus, the
court concluded “newly developed plant breeds fall within the terms of § 101,
and that neither the PPA nor the PVPA limits the scope of § 101’s coverage.”246
The Supreme Court further explored seed patents in Bowman v. Monsanto
Co.247 Monsanto owned a patent on a genetically modified soybean known as
the “Roundup Ready” seed, which could survive exposure to certain
herbicides.248 Under a special licensing agreement, the seed could be sold to a
grain elevator or the resulting crop could be consumed for personal use or sold
in commercial markets.249 The license did not permit breeding, even though it
was possible.250 Since the seed’s resistance to certain herbicide came from a
genetic trait, the trait could be passed down to seeds produced by the resultant
crop.251
A farmer named Vernon Bowman sought to circumvent the special licensing
agreement and avoid paying premium prices for the Roundup Ready seed.252
Instead of purchasing the seeds, Bowman purchased an assortment of
commodity seeds from a grain elevator.253 The batch he purchased contained
Roundup Ready seeds intermixed with other seeds.254 Bowman planted all the
seeds and then applied a glyphosate herbicide.255 This method killed all the
240 How Do I Read A Patent? The Claims, BROWN AND MICHAELS, http://www.bpmlegal.com/ho
wtopat5.html (last visited Oct. 20, 2015).
241 Plant v. Utility, supra note 236.
242 Id.
243 Id.
244 At the time of the opinion, the Court noted utility plant patents had been granted for “at
least 16 years.” Id. at 144.
245 Id. at 143–44.
246 Id. at 145.
247 133 S. Ct. 1761 (2013).
248 Id. at 1764. The patent for this seed is U.S. Patent No. 5,352,605.
249 Id.
250 Id.
251 Id. at 1765.
252 Id.
253 Id.
254 Id.
255 Id.
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non-Roundup Ready seeds and revealed the crops with the patented herbicideresistant genetic trait.256 Bowman harvested these crops, saved the seeds, and
replanted the patented Roundup Ready seed without paying Monsanto.257
Monsanto sued Bowman for patent infringement of its Roundup Ready
seed.258 Bowman raised the patent exhaustion defense.259 The district court
found Bowman infringed on Monsanto’s patents and the Federal Circuit
affirmed.260
The Supreme Court held the patent exhaustion doctrine does not permit a
farmer to save seeds from resulting crops under Monsanto’s special licensing
agreement.261 The Court explained that the patent exhaustion doctrine
constrains the patent holder’s right to control another’s right to a particular
article of the patented invention.262 Once the patentee has received a reward
for the particular article of the patented product, he or she retains no further
control.263 However, the patentee maintains the ability to prevent the buyer to
reproduce the particular article of the patented technology.264 Based on this
rationale, the Supreme Court held Bowman was not entitled to the patent
exhaustion defense while he had a right to use the original seeds he purchased,
he needed Monsanto’s permission to harvest reproduced seeds from their
patented Roundup Ready seeds.265
In examining plant patents, the Court considered the Pioneer case and the
PVPA.266 Here, the Court reaffirmed that a patent holder of a genetically
modified seed, but not a holder of a PVP certificate, can preclude a buyer from
saving seeds from the resulting crop.267 The court referred back to the Pioneer
case, which concluded the “Patent Act, unlike the PVPA, contains ‘no
exception’ for ‘saving seed.’ ”268 Thus, buyers of a patented seed under § 101
could not save, and subsequently, breed the seed. The Court reasoned a patent
would dramatically decrease in value after the first transaction if farmers could

256
257
258
259
260
261
262
263
264
265
266
267
268

Id.
Id.
Id.
Id.
Id.
Id. at 1763.
Id.
Id.
Id.
Id. at 1766.
Id. at 1767.
Id.
Id.
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save seeds from the patented plant269 and create stockpiles of herbide resistant
seeds.
Bowman countered that the exhaustion defense applied in this case because
farmers normally harvest seeds from crops for subsequent growing seasons.270
In dismissing this argument, the Court equated harvesting seeds from the
resulting crop to making a new product.271 In the alternative, Bowman argued
that seeds naturally self-replicate, and thus, it was the planted seed that violated
the patent, not Bowman.272 The Court concluded Bowman’s conduct made
him more than a passive observer; rather, he maintained reproduction of the
seeds for eight generations.273
In the concluding paragraph of the opinion, the Court limited its holding to
Bowman’s seed reproduction and not to other self-replicating technologies.274
The Court declined to address patent exhaustion scenarios where the selfreplication happens outside the purchaser’s control or self-replication is a step
in using the particular article for another purpose.275
It is fairly clear that a plant can be patented through either a utility patent or
a plant patent, or can receive patent-like protections under a PVPA certificate.
However, cannabis presents another unique issue: can someone patent a plant
that society considers harmful or immoral? This question invokes a concept in
patent law known as the moral utility doctrine, which means, “not be frivolous,
or injurious to the well-being, good policy, or good morals of society.”276
Considering the moral utility in a patent is virtually irrelevant if a utilitarian
purpose exists. In Juicy Whip, Inc. v. Orange Bang, Inc., the Federal Court
considered this moral utility doctrine277 and found that a patent is not invalid
because it could be used for an immoral purpose.278 Juicy Whip, Inc. owned a
patent279 for a drink dispenser with a simulated pre-mix tank on top of the
dispenser.280 The tank gives the visual impression as if the tank is the principal
Id. at 1768.
Id.
271 Id.
272 Id. at 1768–69.
273 Id. at 1769.
274 Id.
275 Id.
276 Lowell v. Lewis, 1 Mason 82 (Cir. D. Mass. 1817), abrogated by In re Fisher, 421 F.3d 1365,
1371 (Fed. Cir. 2005).
277 Juicy Whip, Inc. v. Orange Bang, Inc., 185 F.3d 1364 (Fed. Cir. 1999).
278 Id. at 1368.
279 POST-MIX BEVERAGE DISPENSER WITH AN ASSOCIATED SIMULATED VISUAL DISPLAY OF
BEVERAGE, U.S. Patent No. 5,575,405 (filed Apr. 18, 1996) (issued Nov. 19, 1996).
280 185 F.3d at 1365.
269
270
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source of the bowl’s contents; however, the true source of the beverage is
mixed immediately before being dispensed underneath the cabinet.281 Juicy
Whip sued Orange Bang, Inc. for a patent infringement claim.282 Subsequently,
Orange Bang, Inc. successfully moved for summary judgment at the district
court level, holding that Juicy Whip’s patent was invalid because it lacked utility
and could not be patented under § 101.283
On appeal, the Federal Circuit overturned the judgment of the district court
because there was no basis to hold that the invention lacked utility simply
because it could fool some members of the public.284 The Federal Circuit
reasoned the threshold for finding an invention satisfied utility is only whether
that invention is capable of providing some identifiable benefit.285 The Court
held that the fact one product could be held to look like another invention is a
specific benefit in itself.286
Even though the invention may deceive customers, the utility requirement
was not a mandate for the USPTO to serve as arbiters of deceptive trade
practices.287 Rather, the Court found this decision best left to other
administrative agencies, like the Food and Drug Administration, to protect
consumers from fraud and deception.288
While the Supreme Court has not specifically decided on the doctrine of
moral utility, it has identified a categorical exclusion to patentable subject
matter, notwithstanding a product’s utilitarian value. In Bilski v. Kappos,289 the
Supreme Court held the “machine-or-transformation test” is not the sole test
for determining the patent eligibility of a process.290 In affirming the Federal
Circuit opinion, the Court addressed three specific exceptions to patentable
subject matter under § 101. In referencing the Chakrabarty opinion, the Bilski
Court found only “laws of nature, physical phenomena, and abstract ideas”291
are not patentable under § 101. Outside of these exceptions, the Bilski Court
found Congress took a broad, permissive approach to patent eligibility under

281
282
283
284
285
286
287
288
289
290
291

Id.
Id. at 1366.
Id.
Id. at 1368.
Id. at 1366.
Id. at 1367.
Id. at 1368.
Id.
561 U.S. 593 (2010).
Id. The facts underlying the opinion are not relevant to this analysis.
Id. at 601.
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§ 101.292 In the aftermath of Bilski, it appears the Supreme Court interpreted
§ 101 broadly to include many areas for innovation as long as an invention does
not fall into one of the aforementioned categorical exclusions.
While the aforementioned cases do not specifically address whether a strain
of marijuana is patentable, they may provide guidance by analogy for this form
of novel patentable subject matter.
G. CURRENT PATENTS GRANTED FOR CANNABIS AND PATENT PENDING
DEVELOPMENTS

While the Federal Government explicitly prohibits cannabis possession, use,
distribution, and cultivation under the CSA, ironically, the federal government
itself owns a patent for cannabis. U.S. Patent No. 6630507, named
“Cannabinoids as Antioxidants and Neuroprotectants” was issued on October
7th, 2003. The patent abstract states:
Cannabinoids have been found to have antioxidant properties,
unrelated to NMDA receptor antagonism. This newfound
property makes cannabinoids useful in the treatment and
prophylaxis of wide variety of oxidation associated diseases, such
as ischemic, age-related, inflammatory and autoimmune diseases.
The cannabinoids are found to have particular application as
neuroprotectants, for example in limiting neurological damage
following ischemic insults, such as stroke and trauma, or in the
treatment of neurodegenerative diseases, such as Alzheimer’s
disease,
Parkinson’s
disease
and
HIV
dementia.
Nonpsychoactive cannabinoids, such as cannabidoil, are
particularly advantageous to use because they avoid toxicity that
is encountered with psychoactive cannabinoids at high doses
useful in the method of the present invention.293
The patent does not give the federal government a patent on the cannabis plant
because the plant is a product of nature. It rather patents a method of use of a

292 Id. The Court took a broad permissive approach “to ensure that “ ‘ingenuity should receive
a liberal encouragement.’ ” Id. (quoting Diamond v. Chakrabarty, 447 U.S. 303, 308–09 (1980)).
293 Cannabinoids as Antioxidants and Neuroprotectants, U.S. Patent No. 6630507 (filed Feb. 2,
2001) (issued Oct. 7, 2003).
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non-psychoactive cannabinoid compound for treating some diseases.294 The
patent does not claim a composition of matter or a compound, but rather a
method for using specific cannabinoids for treating oxidative stress.295 Other
marijuana patents have been granted for methods of use and marijuana
associated products, but none have been granted for particular cannabis
strains.296
Today, a medical marijuana product exists as a consumable product in the
prescription drug industry. On May 31, 1985, the Federal Drug Administration
(FDA) approved Marinol for marketing in the United States.297 Marinol
incorporates Dronabinol in soft gelatin capsules.298 Dronabinol is a synthetic
delta-9-tetrahydrocannibinol, commonly known as THC.299 The purpose of
Marinol is to treat “anorexia with weight loss in patients with AIDS”300 and
“nausea and vomiting associated with cancer chemotherapy in patients who
have failed to respond adequately to conventional antiemetic treatments.”301
Side effects for the drug could include abdominal pain, nausea, vomiting,
amnesia, anxiety, confusion, depersonalization, dizziness, euphoria,
hallucination, paranoia, somnolence, and “thinking abnormal.”302 “[Marinol]
ha[s] been through FDA’s rigorous approval process and [has] been determined
to be safe and effective.”303 The FDA approval process necessitates “solid
clinical data” along with “a scientifically based assessment of the risks and
benefits” to assess the therapeutic value of drugs.304
294 Andrew Chadeayne, Does U.S. Patent No. 6,630,507 Give the Government Ownership of
Marijuana?, INVESTING PATENTS-OWNING IDEAS, http://inventingpatents.com/us-patent-66305
070-methods-using-marijuana/ (last visited Nov. 15, 2015).
295 Id.
296 For more information, view the USPTO Patent Full-Text and Image Database and search
for “cannabis.” USPTO Patent Full-Text and Image Database, http://patft.uspto.gov/netacgi/
nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.ht
ml&r=0&f=S&l=50&TERM1=cannabis&FIELD1=&co1=AND&TERM2=&FIELD2=&d=P
TXT (last visited Nov. 15, 2015).
297 Testimony of Robert J. Meyer, M.D., http://www.fda.gov/newsevents/testimony/ucm1147
41.htm.
298 Marinol, http://www.fda.gov/ohrms/dockets/dockets/05n0479/05N-0479-emc0004-04.pdf
(last visited Nov. 15, 2015).
299 Id.
300 Id.
301 Id.
302 Id. In clinical trials, the incidence rates of the side effects were 3% to 10%. Id.
303 Testimony of Robert J. Meyer, M.D., http://www.fda.gov/newsevents/testimony/ucm114
741.htm (last visited Nov. 15, 2015).
304 Id. Any drug marketed in the United States must undergo rigorous scientific testing under
the Pure Food and Drug Act of 1906. Http://www.dea.gov/divisions/sea/in_focus/marinolcessmet.pdf (last visited Nov. 15, 2015).
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Marinol is a Schedule III drug305 regulated under the CSA, and is considered
“abusable.”306 The DEA helped facilitate research of THC’s therapeutic effects
on nausea and vomiting in the early 1980s.307 The research led to classification
of Marinol as a Schedule III drug.308 In a 1999 report by the Institute of
Medicine, the Institute did not recommend smoked marijuana for diseases
treatable by cannabinoids, but it found that compounds in marijuana could be
isolated in purified and synthetic forms in pharmaceuticals.309
While Marinol’s legality as a controlled substance indicates the federal
government is open to legalizing THC-like substances, it has never allowed a
patent of a cannabis strain. Scarce to no legal precedent exists for cannabis
varieties. In fact, many cannabis varieties are patent-pending before the
USPTO.310 But, the USPTO has not granted a patent to a cannabis strain yet.311
According to the Jason Blevins, a writer for the Denver Post, “[t]he U.S. Patent
and Trademark Office has rejected cannabis-related patents consistently,
arguing that the invention is ‘immoral and scandalous’ because marijuana is
illegal or that the invention has no useful purpose because its use violates
federal drug law.”312 An eager grower can file a standard patent application
with the USPTO, but he or she will likely run into federal inaction.313 Further,
the USPTO website states, “the average patent application pendency is 24.6
months.”314 Given that it will take two years from the date of filing to reach a
305 According to the DEA, “Schedule III drugs, substances, or chemicals are defined as drugs
with a moderate to low potential for physical and psychological dependence. Schedule III drugs
abuse potential is less than Schedule I and Schedule II drugs but more than Schedule IV.” Drug
Schedules, http://www.dea.gov/druginfo/ds.shtml (last visited Nov. 15, 2015).
306 Marinol, http://www.fda.gov/ohrms/dockets/dockets/05n0479/05N-0479-emc0004-04.pdf
(last visited Nov. 15, 2015).
307 Pharmaceutical products already exist, called Marinol and Cesamet. Http://www.dea.gov/
divisions/sea/in_focus/marinol-cessmet.pdf (last visited Nov. 15, 2015).
308 Id.
309 Id.
310 For an example of a patent-pending cannabis strain that is still in application phase, see, Patent
Application 61923707, United States Patent and Trademark Office Patent Application Full Text and
Image Database, http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1
&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=24&f=G&l=50&co1=AND&=PG01&s1=c
annabis.CLM.&OS=ACLM/cannabis&RS=ACLM/cannabis (last visited Oct. 20, 2015).
311 Hilary Bricken, The Possibility of Marijuana Plant Patents, http://abovethelaw.com/2015/07/th
e-possibility-of-marijuana-plant-patents/ (last visited Oct. 20, 2015).
312 Jason Blevins, Pot Grower’s Quest: U.S. Patent Protection for Cannabis Seeds, http://www.thecan
nabist.co/2014/12/24/cannabis-seeds-pot-growers-us-patent-protection/25975/2/ (last visited
Oct. 20, 2015).
313 Id.
314 Patent FAQs, UNITED STATES PATENT AND TRADEMARK OFFICE, http://www.uspto.gov/
help/patent-help (last modified Dec. 13, 2014).
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patent grant or denial, the only benefit from the patent application process a
grower can hope for is a patent-pending designation315 on his or her strain.
III. ANALYSIS
The legal muddle explained above provides little guidance for whether
cannabis strains are patentable, and a cannabis strain has never been patented.
While case law from the Federal Circuit provides some guidance for plant
patents in the corn industry,316 it is unclear whether a plant patent can be issued
for a cannabis variety. Thus, growers are left in legal limbo.
Initially, since the cannabis plant is a product of nature, it cannot be
patented.317 Thus, while naturally occurring compounds are not patentable,
synthetic compounds and purified components of marijuana are patentable as
chemical inventions.318 Additionally, new combinations of the molecules found
in marijuana are patentable.319
First, this Part will establish the underlying issues for cannabis variety
patents. This Part will then analyze the major impediments to patentability and
the underlying rationale for those obstacles. This Part will also evaluate some
clear answers that have emerged from analogous patent law. Further, this Part
will suggest a legal analytical framework for growers seeking to patent their
respective cannabis strains. This framework considers salient questions of
patent law: what avenues a cultivator could choose for his or her cannabis
variety patent, the current federal prohibition, and its effect on cannabis variety
patents. Next, this Part will answer the central question posed by this Note:
whether a cannabis strain is patentable, and how a grower could go about
receiving legal protection for their strain. Given the current state of federal law,
this Part will assert that cannabis strains are patentable, using analogous case
law and the underlying policy of patent law in general. Finally, this Part will
address potential legislative developments that may change the analytical
framework and the conclusion reached by this Note.

315 “When a patent application is pending, the manufacturer is able to use the term ‘patentpending’ on the product or in advertisements.” Bonnie Grant, Deficiencies and Proposed Recommendation
to the False Marking Statute: Controlling Use of the Term ‘Patent,’ 12 J. INTELL. PROP. L. 283 (2004).
316 See Monsanto Co., 133 S. Ct. at 1761; see also Pioneer, 534 U.S. at 124.
317 Does U.S. Patent No. 6,630,507 Give the Government Ownership of Marijuana?, http://
inventingpatents.com/us-patent-66305070-methods-using-marijuana/ (last visited Nov. 15, 2015).
318 Patenting Marijuana Technology, INVENTINGPATENTS.COM, http://inventingpatents.com/patent
ing-marijuana-technology/ (last visited Nov. 15, 2015).
319 Id.
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A. PATENTABILITY OF CANNABIS VARIETIES: A CLEARER PICTURE OF THE
UNDERLYING ISSUES

While the legal environment surrounding cannabis variety patents remains
murky, there are some clearly definable issues and answers. The prospective
patentee must understand what undercuts the potential patent.
The main impediment to patentability for cannabis varieties is the CSA.320
Under the CSA, the DEA has labeled cannabis as a Schedule I drug, meaning it
has no medically accepted benefit and is highly susceptible to abuse. While
many states legalized marijuana for medical and recreational use,321 cannabis is
federally prohibited. Pursuant to the CSA, the federal government can arrest
state residents despite comporting with state marijuana laws, according to the
Gonzales decision.322 As a result, growers will need to find a way around the
CSA.
This impediment has several practical impacts on the cannabis cultivation
trade. First and foremost, it makes cannabis cultivation illegal. As a result,
when cannabis cultivators apply to the patent process, they are essentially
admitting to a federal crime.323 Cannabis cultivators thus risk criminal
prosecution simply by applying for a patent. Further, one purpose of the CSA
is to limit the supply of cannabis in the market.324 The cultivation of cannabis
varieties increases the supply of cannabis in general. Therefore, the federal
prohibition serves as a deterrent to cannabis cultivation, thereby limiting the
supply in drug markets, and opportunities for innovation.
While the CSA has effectively prevented marijuana cultivation from
developing legal precedent in the patent arena, some clear answers exist in
current patent law. A patent for an extracted component of cannabis exists for
the federal government.325 Therefore, it appears that cannabis is clearly
patentable; however, this patent is materially limited. A further analysis of the
patent shows this patent does not exist for the cannabis plant, but rather for a
non-psychoactive cannabinoid compound derived from the plant.326 Thus, the
question as to whether cannabis varieties are patentable has not been answered.
Controlled Substances Act, 21 U.S.C. § 801 (1970).
See COLO. CONST. art. XVIII, § 16 (2013); see also WASH. ADMIN. CODE §§ 314-55-005
through 314-55-540 (2013). Recently, Oregon, Alaska, and the District of Columbia have
legalized recreational marijuana.
322 545 U.S. at 29.
323 Interview with Joseph Miller, January 4th, 2015, by this Note’s Author.
324 The Controlled Substances Act, 21 U.S.C. § 801 (1970).
325 Cannabinoids as Antioxidants and Neuroprotectants, U.S. Patent No. 6630507 (filed Feb. 2,
2001) (issued Oct. 7, 2003).
326 Id.
320
321
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Additionally, a synthetic cannabis supplement, Marinol, is readily available for
states that have legalized medical marijuana. While it appears the federal
government has admitted cannabis compounds have medicinal uses by
admitting Marinol as a Schedule III drug, this still leaves the cannabis variety
patent question open. Therefore, while there are promising answers in this legal
miasma, a genuine uncertainty remains for the patentability of unique cannabis
varieties.
B. THE ANALYTICAL FRAMEWORK FOR GROWERS

Given the outstanding legal question as to whether cannabis varieties are
patentable, many corollary questions surrounding cannabis varieties have
developed.
The first question a cultivator must ask is whether the cannabis strain is
patentable? Initially, a cultivator must determine whether the cannabis product
occurs naturally, or is a unique cannabis variety either sexually or asexually
reproduced. In order to answer this threshold inquiry, the cultivator must
decide to pursue one of three routes: utility patents, PPA, or the PVPA.
Since utility patents afford the highest level of legal protection for
intellectual property, they are the hardest to attain.327 While a cultivator can
develop a new composition of matter theoretically attainable under § 101,
evidenced by the utility patents granted in Pioneer, the cultivator actually needs
to develop a new composition of matter. This may be above the pay grade of
the average botanist and require sophisticated laboratory technology.
As a result, it is more prudent for a cultivator to apply for a plant patent
under the PPA. Plant patents are more easily attainable than utility patents
because fewer elements need to be proven in the patent application process.
The precedent set forth in Pioneer indicates this is entirely possible. The only
restriction on plant patents is that the variety must be asexually reproduced,
thereby limiting the vast possibilities of genetic recombination through sexual
reproduction. Additionally, since asexual reproduction can only be rendered
from one mother plant,328 this may create more cost for the cultivator because a
mother plant must be grown before an asexually reproduced plant can be
patented.
Thirdly, cultivators can seek protection through a PVP certificate under the
PVPA. PVP certificates grant patent-like protections for sexually reproduced

327 Utility patents require the showing of four elements: Novelty, statutory, nonobvious, and
Usefulness. See supra Part II.
328 Wooster, supra note 184, § 2.
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plants. All the grower must prove for a PVP certificate is that the cannabis
variety is new, distinct, uniform, and stable. Thus, growers can receive legal
protection for cannabis seeds and uncultivated plants. However, there are some
drawbacks to this patent route. PVP certificates are granted by the Department
of Agriculture, not the USPTO. The USPTO has more expertise in dealing
with patents generally, whereas the Department of Agriculture dedicates only
one office to Plant Variety Patents. Further, a PVP certificate has no claims on
the scope of protection, whereas plant patents have one claim defining the
bounds of protection. Thus, PVP certificates do not afford the full amount of
protection afforded by a plant patent under the PPA.
A cannabis cultivator needs to thoroughly ascertain the details of the
cultivation process needed to complete a valid patent application. Before
submitting the patent application, the cannabis cultivator must determine if the
federal government will deny the patent because cannabis is a Schedule I drug
and illegal at the federal level. However, the Juicy Whip precedent suggests that
the fact that cannabis is illegal under the CSA has no merit in the patent
application process. As long as cannabis has an identifiable utilitarian benefit, it
satisfies the usefulness requirement, and here, a cultivator can point the medical
benefits of cannabis. While the court in Juicy Whip did not consider a patented
product that was inherently illegal329 like cannabis, this Federal Circuit case
clearly establishes that the USPTO does not look to moral utility in a patent
application.330
Next, the cannabis cultivator will need to assess an important risk: criminal
liability. The pertinent question is whether the patent application serves as an
admission to a federal crime. Since the patent process is an incredibly detailed
process, a cannabis cultivator will need to fully elucidate the details of the
activities engaged in to develop a new cannabis variety in order to complete a
valid patent application. Details about cultivation include growing methods,
harvesting, and many other ways of cultivating the cannabis plant. Further,
patent applicants will need to delve into further specificity of their innovation
by proving the metes and bounds of their patent claims. While patent claims
only apply to plant and utility patents, PVP certificates still must divulge
information about the cannabis strain to the federal government to fulfill the
necessary elements for the certificate. Since cultivation of marijuana is a federal
crime under the CSA, the prospective patentee will be reporting facts that

329 The product in this case was a drink machine. Id. at 1365–68. By contrast, cannabis is
inherently illegal under the CSA.
330 Even though the Federal Circuit has established no moral utility, it is still unclear what the
Supreme Court will determine.
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constitute an admission of criminal wrongdoing. Given that the acts
undertaken to innovate are also acts that are punishable as crimes, a person
could technically engage in them, but only at the cost of putting themselves in
danger of being criminally prosecuted. Here, if the grower is willing to take the
risk and fails, he or she may enjoy patent protection for their cannabis variety
from the confines of a federal penitentiary.
C. ALTHOUGH CANNABIS IS A SCHEDULE I DRUG UNDER THE CSA, POLICY
CONSIDERATIONS UNDERLYING PLANT PATENTS AND THE FEDERAL CIRCUIT
CASE LAW INDICATE CANNABIS VARIETIES ARE LIKELY PATENTABLE

Although cannabis is a Schedule I drug under the CSA, cannabis strains are
likely patentable because the USPTO does not look into the moral utility of a
patent. From the face of the CSA, a grower may believe a cannabis variety
patent is unattainable, given that cannabis cultivation is illegal at the federal
level. However, there is no provision in the text of the CSA prohibiting patent
protection, through utility patents, PPA, or the PVPA. It is safe to assert that
the CSA did not contemplate patent law at all, but rather only criminal
sanctions for cannabis possession and production. Assuming the cannabis
variety cultivated is unique and not a product of nature or another categorical
exclusion under the Bilski precedent,331 a grower will theoretically receive a
patent through proof of the creation of the variety and satisfactory completion
of the patent application requirements.
As an initial matter, under Juicy Whip, the USPTO will not look to the moral
utility of the invention. So long as the patent is written broadly enough to
encompass a legitimate purpose, the fact that the invention’s use is immoral
does not affect its patentability. However, while there are good business
reasons for making cannabis strains patentable, patent law usually ignores
business considerations when determining patentability. Thus, cannabis strains
likely do not violate the usefulness requirement.
Additionally, under Bowman and Pioneer, a cultivator can receive a patent for
plants or a PVP certificate. Further, a grower can likely preclude purchasers of
his or her plant patent from saving seeds and growing new batches. Thus, it
appears that if cannabis varieties are plants and can be either sexually or
asexually reproduced, they are patentable. Moreover, nothing in the Bilski
precedent precludes the broad patentable subject matter of § 101, unless a
product is a product of nature, physical phenomena, or an abstract idea. As

331 The specific categorical exemptions are products of nature, physical phenomena, and
abstract ideas. Bilski, 561 U.S. at 601.
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long as the cultivator can show he engineered the variety in aid of nature, the
cultivator will likely get around the products-of-nature exclusion.
Furthermore, the policy considerations underlying patent law support the
patentability of cannabis strains. The fundamental purpose of patent law is
encouraging innovation of utilitarian works.332 Assuming cannabis varieties
serve a utilitarian purpose—and medical evidence suggest they do333—
providing patents for cannabis varieties promotes innovation in an industry ripe
with opportunity. Cannabis cultivators will likely develop the best strains in the
hopes of achieving legal legitimacy and protection from the federal government.
The possibilities for invention and innovation are limitless. Preclusion of
cannabis variety patents would likely result in a chilling effect on the cannabis
industry as a whole. As a result, the possibility that new varieties are discovered
will diminish dramatically, which likely will have a substantial adverse impact on
the development of this emerging industry. Given that states like Colorado and
Washington use revenues from marijuana sales to fund public goods, growth in
the cannabis industry can funnel more money in educational projects and other
public funds. This benefits society in addition to the billions of dollars saved
on law enforcement and correctional facility costs. Furthermore, assuming
cannabis does have a medical use, innovation in cannabis varieties may catalyze
the development of unimagined pharmaceutical drugs and spur entirely new
industries. But, much of these hypothetical benefits are likely not possible
without an economic incentive, namely, the limited monopoly afforded by
patent law.
Currently, economic barriers created by the CSA have limited the
investment flowing into the cannabis industry. Many venture capitalists and
angel investors are wary of the cannabis industry for two reasons: one, potential
criminal liability, and two, the industry is not the type traditionally financed by
venture capital funds.334 While venture capitalists and cannabis cultivators are
understandably wary of the first reason, lack of quality in the industry may be
alleviated by the provision of cannabis variety patents. If cannabis varieties are
patentable, the cannabis industry gains much-needed credibility, which it
currently lacks.
By providing this credibility, legal protection would
consequently provide a catalyst for capital investment. Therefore, the
development of patent law in the corn industry, the virtual nonexistence of the
moral utility doctrine, and the strong policy rationales underlying patent law
support the idea that cannabis varieties should be patentable.
332
333
334

Sartori, supra note 153, at 336 (discussing the economic incentives theory in patent law).
See supra note 93.
Ohmer, supra note 59, at 113–14.
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D. LEGISLATIVE DEVELOPMENTS THAT CAN CHANGE THE LEGAL
ENVIRONMENT

While cannabis varieties are likely a patentable subject matter, legislative
enactments, executive action, and administrative capitulation by the USPTO
can provide more assurance for a cannabis cultivator that his or her variety is
patentable. The CSA was a product of congressional action. Accordingly,
Congress is in the best position to effectuate change favoring cannabis variety
patents. Congress could expressly allow cannabis patents through law.
More feasibly, Congress could allow the Attorney General to give states with
regulatory schemes immunity from federal prosecution under the CSA. This
could potentially resolve the conflict between state and federal laws on
marijuana legalization. The federal government would then have leverage in
ensuring state compliance with federal drug enforcement objectives, while also
resolving the fear of federal prosecution on the part of those growers operating
legally in states. Conversely, Congress could also specifically prohibit cannabis
variety patents by statute. Here, the issue is not Congress’s constitutional
authority to act, but rather those political realities of congressional legislation.
Executive action by the President could also effectuate change in this legal
environment. The President could reschedule marijuana from a Schedule I to a
Schedule II drug and this seems like more of a reality in the wake of former
Attorney General Eric Holder’s comments in favor of this move. This would
drastically change the legal environment. Such a move will likely be politically
motivated, as it rests with the president’s discretion. Furthermore, the federal
government could choose not to prosecute the person making a cannabis
variety claim. It appears from the Department of Justice memo that this may
occur because such prosecution does not fulfill the priorities of federal
enforcement.335 However, this still leaves open significant risk to the
prospective cannabis variety patent applicant because there is always uncertainty
about prosecutorial discretion.
Finally, if the patent-pending cannabis strain is granted by the USPTO, the
precedent for marijuana strains is clear: it is allowed. Currently, the USPTO has
not granted a cannabis strain patent citing marijuana’s illegality under federal
335 Justice Department Announces Update to Marijuana Enforcement Policy, United States Department
of Justice (2013), http://www.justice.gov/opa/pr/justice-department-announces-update-marijua
na-enforcement-policy (explaining the federal enforcement priorities emphasize prevention of
distribution to minors, distribution to criminal enterprises, distribution to states where marijuana
is illegal, using marijuana as a cover for other drugs, use of firearms in distribution of marijuana,
impaired driving and other adverse consequences, growing on public lands, and possession or use
of marijuana on public lands).
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law.336 Therefore, cannabis strains will not be issued without USPTO
capitulation. Capitulation will likely not happen. However, in the event
cannabis strains become patentable through congressional, executive, or
administrative action, cannabis variety patents will likely emerge as a new
patentable subject matter ripe for innovation.
IV. CONCLUSION
With its gradual legitimization, the cannabis industry is ripe for innovation.
Embedded within this industry is the emergence of a new patentable subject
matter: cannabis variety patents. While virtually unregulated before the turn of
the twentieth century, cannabis endured more than a century of stigmatization
and regulation, ultimately leading to its illegality nationwide through the
Controlled Substances Act. Currently, marijuana is a Schedule I narcotic,
meaning it has a high potential for abuse and no accepted medical uses.
However, the times are changing. Many studies today indicate more public
support for marijuana decriminalization and legalization. In the face of the
federal prohibition, many states like Colorado and Washington have not only
legalized marijuana for medical use, but also for recreational use. Recently, the
Department of Justice, the entity that prosecutes federal criminal offenses for
possession and cultivation of marijuana, issued a memorandum indicating it
would not employ its limited prosecutorial resources against individuals and
businesses in states that have legalized cannabis recreationally, as long as the
states have strict regulatory schemes in place. Furthermore, the federal
government itself has patented a method-of-use for cannabis and has approved
a drug utilizing synthetic THC to treat many medical ailments.
Yet, while a marijuana patent exists, no patents have been issued for
cannabis variety strains. Despite this fact, case law from the Supreme Court
and the Federal Circuit, along with persuasive policy considerations, suggest
that a cannabis strain is patentable. If patentable, a grower could receive patent
protection through one of three avenues: utility patents, plant patents, or the
Plant Variety Protection Act certificates.
However, despite these favorable indications, the CSA is a virtually
impervious barrier to patentability. Federal law reigns supreme over state
legalization, as held in the Gonzales precedent. Patent law is exclusively within
federal jurisdiction, and consequently, the legal domain follows federal law.
336 Jason Blevins, Pot Grower’s Quest: U.S. Patent Protection for Cannabis Seeds, http://www.thecannabi
st.co/2014/12/24/cannabis-seeds-pot-growers-us-patent-protection/25975/2/ (last visited Oct. 20,
2015).
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Cultivators who apply for patent protection must be wary of the federal ban
because details divulged during the patent application likely constitute
admissions to a federal crime under the CSA. There are solutions to this
problem. Congress could resolve the conflict between federal and state laws
through a statute. The president could change the Schedule I status of cannabis
to Schedule II or less. Or, the USPTO could capitulate and outright issue a
patent for a cannabis strain. However, unless some legal change occurs,
cannabis strains are not patentable.
Cannabis cultivators and venture capitalists are eager to see where federal
law is going in light of state legalization and changing political realities. Legal
developments surrounding cannabis at the federal level are likely to occur in the
near future. For any real change to happen, the federal government must act.
One thing is for certain, however: a small window of opportunity in this
industry will propel it to new highs.
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